Stock listing

Lang & Schwarz:A41BQ3 Cellectar Biosciences, Inc. Aktie

German listing (Lang & Schwarz) of Cellectar Biosciences, Inc. · home listing NASDAQ:CLRB

Follow Cellectar Biosciences, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CLRB

$1.14 USD -0.05 (-4.2%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CLRB

Cellectar Biosciences, Inc. logo
Ticker
Lang & Schwarz:A41BQ3
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Calls

Replays

  • Cellectar Biosciences (NASDAQ:CLRB) Q2 2026 Earnings Call

    Thu, Aug 13, 2026 · 8:30 AM ET

    Watch Transcript

  • Cellectar Biosciences (NASDAQ:CLRB) Q1 2026 Earnings Call

    Thu, May 14, 2026 · 8:30 AM ET

    Watch Transcript

  • Cellectar Biosciences (NASDAQ:CLRB) Q4 2025 Earnings Call

    Wed, Mar 04, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia

Oct 15, 2026

Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia

Sep 29, 2026

Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 13, 2026

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026

Jul 30, 2026

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Jul 15, 2026

Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting

Jun 1, 2026

Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 14, 2026

Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026

May 11, 2026

Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia

May 5, 2026

Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026

Apr 21, 2026

All Cellectar Biosciences, Inc. news

Decks

Cellectar Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 160 in all · newest Oct 15, 2026 · oldest 2019
Calls
12 calls with a replay · 12 with a transcript · latest Aug 13, 2026
Decks
23 decks · latest October 2026

Where Cellectar Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CLRB · Home listingNASDAQUnited StatesUSD
BOATS:CLRBBOATSUnited StatesUSD
gettex:NV40gettexGermanyEUR
LS Exchange:A41BQ3LS ExchangeGermanyEUR
Frankfurt:NV40FrankfurtGermanyEUR
Lang & Schwarz:A41BQ3 · This pageLang & SchwarzGermanyEUR
Munich:NV40MunichGermanyEUR

Log in to ask 6ix AI your own questions about Cellectar Biosciences, Inc.